124 related articles for article (PubMed ID: 10431685)
1. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
[TBL] [Abstract][Full Text] [Related]
2. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
3. cDNA sequence analysis of monoclonal antibody FU-MK-1 specific for a transmembrane carcinoma-associated antigen, and construction of a mouse/human chimeric antibody.
Arakawa F; Yamamoto T; Kanda H; Watanabe T; Kuroki M
Hybridoma; 1999 Apr; 18(2):131-8. PubMed ID: 10380012
[TBL] [Abstract][Full Text] [Related]
4. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
5. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
Watanabe M; Kubota T; Kitajima M; Hakomori S
Cancer Immunol Immunother; 1993 Sep; 37(4):245-50. PubMed ID: 8348564
[TBL] [Abstract][Full Text] [Related]
6. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
Pendurthi TK; Schlom J; Primus FJ
J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
[TBL] [Abstract][Full Text] [Related]
7. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
Matsumoto H; Liao S; Arakawa F; Ueno A; Abe H; Awasthi A; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(4):2001-7. PubMed ID: 12174877
[TBL] [Abstract][Full Text] [Related]
8. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
9. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
[TBL] [Abstract][Full Text] [Related]
10. Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice.
Qi Y; Moyana T; Bresalier R; Xiang J
Gastroenterology; 1995 Dec; 109(6):1950-7. PubMed ID: 7498661
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice.
Takahashi H; Nakada T; Puisieux I
Science; 1993 Mar; 259(5100):1460-3. PubMed ID: 8451642
[TBL] [Abstract][Full Text] [Related]
12. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Primus FJ; Pendurthi TK; Hutzell P; Kashmiri S; Slavin DC; Callahan R; Schlom J
Cancer Immunol Immunother; 1990; 31(6):349-57. PubMed ID: 2386980
[TBL] [Abstract][Full Text] [Related]
13. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
Pendurthi TK; Parker R; Schlom J; Primus FJ
Int J Cancer; 1990 Dec; 46(6):1021-8. PubMed ID: 2123477
[TBL] [Abstract][Full Text] [Related]
16. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
18. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
[TBL] [Abstract][Full Text] [Related]
19. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
